Key Stats for Novo Nordisk Stock
- Current Price: $40.52
- Target Price (Mid, 12/31/30): ~$64
- Potential Total Return: ~57%
- Annualized IRR: ~10% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Few pharmaceutical stocks have unraveled as fast as Novo Nordisk (NVO) in 2026. NVO is down more than 56% from its 52-week high of $81.44, with a max drawdown of 56.46% recorded on March 30, 2026, per TIKR data.
Bulls see a world-class franchise trading at a decade-low valuation. Bears see a business losing ground to Eli Lilly with its best growth years behind it. The key question: Does this collapse represent genuine value, or a value trap?
The most damaging blow came on February 23, 2026, when NVO fell over 16% after CagriSema, its next-generation weight-loss drug combining semaglutide and cagrilintide, failed to demonstrate non-inferiority against Eli Lilly’s tirzepatide in the Phase 3 REDEFINE 4 trial.
CagriSema achieved 23% weight loss after 84 weeks but did not meet the primary endpoint of non-inferiority compared to tirzepatide. CagriSema was supposed to be Novo’s answer to Lilly. After the result, analysts asked the obvious question: why would doctors prescribe a drug that has now been shown to be less effective?
CEO Maziar Doustdar told investors on the earnings call: “Price reduction, in some ways, is our investment for the future and for capturing more patients.” For a company that had grown revenue at a 19.5% five-year CAGR through 2025, per TIKR historical data, guiding for the first revenue decline in the GLP-1 era was a genuine shock.
One positive catalyst arrived on April 14, 2026. NVO shares rose roughly 3% after Novo announced a strategic partnership with OpenAI, with the company saying the collaboration would allow it to analyze datasets “at a scale that was previously impossible.”
Novo is also executing a DKK 15 billion share buyback launched on February 4, with over 11 million shares repurchased through April 10 at an average price of DKK 257.56.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
Is Novo Nordisk Undervalued Today?
Per TIKR data, NVO now trades at an NTM P/E of 11.91x and an NTM EV/EBITDA of 8.98x, against an LTM gross margin of 82.4%, an LTM EBIT margin of 45.5%, and a return on equity of 60.7%. The NTM dividend yield has risen to 4.2%, up from 2.7% a year ago.
For peer context, TIKR’s Competitors page shows Eli Lilly trading at an NTM EV/EBITDA of 20.72x and an NTM P/E of 26.13x. Roche trades at 10.81x NTM EV/EBITDA. Novartis sits at 13.29x. NVO at 8.98x is the cheapest of this group, despite having margins that rival or exceed most of them.
The Wegovy pill (oral semaglutide for weight management, FDA-approved December 22, 2025) is the most important near-term commercial driver. The pill reached roughly 50,000 prescriptions in the week ending January 23, 2026, and was available at over 70,000 U.S. pharmacies. Management described it as “the first and best-in-class oral GLP-1 for weight management” on the Q4 2025 earnings call. Clinical trial data show the pill produced 16.6% weight loss over 64 weeks, compared to approximately 11.2% for Eli Lilly’s rival oral candidate, orforglipron, over 72 weeks, based on respective trial results.
The bear case has substance. Eli Lilly now holds more than 60% of the U.S. obesity drug market, with tirzepatide outpacing semaglutide on volume share. Novo’s 2026 guidance reflects significantly lower U.S. pricing from the Most-Favored-Nations pricing framework, reduced Medicaid coverage of anti-obesity medicines, and Novo’s own decision to cut Wegovy and Ozempic list prices by up to 50% starting January 2027.
Per TIKR estimates, consensus projects 2026 revenue at approximately DKK 285.7 billion, down 7.5% from DKK 309.1 billion in 2025. Goldman Sachs cut combined CagriSema and cagrilintide peak sales estimates by approximately 65% following the REDEFINE 4 result, labeling the stock a “show-me story.”
What the bears may be underweight is the underlying scale. TIKR’s segment data shows the Diabetes and Obesity Care segment generated DKK 289.5 billion in revenue in 2025. Even with a revenue decline in 2026, Novo retains an LTM EBIT margin of 45.5% and an LTM free cash flow that, per TIKR’s estimates page, reached DKK 58.9 billion in 2025. The volume-over-price thesis requires patience, but the business financing that bet is still generating substantial cash.
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $40.52
- Target Price (Mid, 12/31/30): ~$64
- Potential Total Return: ~57%
- Annualized IRR: ~10% / year
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
The TIKR mid-case model targets approximately $64 for NVO by December 31, 2030, implying roughly 57% total return and around 10% annualized IRR from the model entry price of $40.81. The mid case assumes a revenue CAGR of around 6%, driven by global oral Wegovy scaling and eventual CagriSema contribution, with a net income margin of around 32%.
What stands out is that even the low case is constructive. The TIKR low-case scenario targets approximately $76 per share by 12/31/30, implying around 87% total return and roughly 7% annualized IRR, based on a revenue CAGR of around 6% and a net income margin of around 30%. The high case targets approximately $118, implying around 189% total return and roughly 13% annualized IRR. All three scenarios sit well above today’s price of $40.52, suggesting the current market price reflects expectations more bearish than even TIKR’s conservative scenario.
The primary risk is semaglutide concentration. Nearly all of Novo’s revenue flows through its obesity and diabetes franchise. If Wegovy pill volumes disappoint, or if Lilly’s orforglipron matches the pill’s efficacy upon approval, the recovery timeline extends. The Q1 2026 report on August 5, 2026, will be the next major data point on Wegovy pill prescription trajectory and pricing realization. Watch weekly prescription run rates as the key metric for whether the volume-over-price bet is working.
Conclusion
The next key catalyst is the Q1 2026 earnings report. Watch weekly Wegovy pill prescription volumes as the single most important metric for whether Novo’s volume-over-price strategy is gaining traction. Novo Nordisk is a 100-year chronic-disease franchise (founded 1923, per TIKR) trading near a decade-low multiple after three consecutive crises. The TIKR model says the market has more than priced in the bad news. The risk is that more bad news is still ahead.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Novo Nordisk?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Novo Nordisk, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Novo Nordisk alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Novo Nordisk on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
